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Key Points
• The overall response
rate for advanced
phase MPN with deci-
tabine/ruxolitinib ther-
apy was 44% with
a median OS of 9.5
months.
• This combination ther-






Myeloproliferative neoplasms (MPN) that have evolved into accelerated or blast phase
disease (MPN-AP/BP) have poor outcomes with limited treatment options and therefore
represent an urgent unmet need. We have previously demonstrated in a multicenter, phase
1 trial conducted through the Myeloproliferative Neoplasms Research Consortium that the
combination of ruxolitinib and decitabine is safe and tolerable and is associated with
a favorable overall survival (OS). In this phase 2 trial, 25 patients with MPN-AP/BP were
treated at the recommended phase 2 dose of ruxolitinib 25 mg twice daily for the induction
cycle followed by 10 mg twice daily for subsequent cycles in combination with decitabine
20 mg/m2 for 5 consecutive days in a 28-day cycle. Nineteen patients died during the study
follow-up. The median OS for all patients on study was 9.5 months (95% confidence
interval, 4.3-12.0). Overall response rate (complete remission 1 incomplete platelet
recovery 1 partial remission) was 11/25 (44%) and response was not associated with
improved survival. We conclude that the combination of decitabine and ruxolitinib was
well tolerated, demonstrated favorable OS, and represents a therapeutic option for this
high-risk patient population. This trial was registered at www.clinicaltrials.gov as
#NCT02076191.
Introduction
Myeloproliferative neoplasms (MPNs) are chronic hematopoietic stem cell malignancies with the
propensity to evolve into blast phase (BP) disease ($20% blasts in the peripheral blood or bone marrow
[BM]) and accelerated phase disease (AP; 10% to 19% blasts in the peripheral blood or BM).1 The
overall survival (OS) of MPN-BP is ;3 to 5 months. Cytotoxic chemotherapy does not meaningfully
improve outcome.2,3 Increased attention to the distinct molecular signature distinguishing MPN-BP
from de novo acute myeloid leukemia (AML) has led to evaluation of mechanism-based alternative
treatments.4
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Preclinical studies of both murine and primary MPN-BP cells have
demonstrated synergistic anticlonal activity of the hypomethylating
agent decitabine, in combination with the selective JAK1/JAK2
inhibitor, ruxolitinib.4 We have previously reported the results
of a multicenter, phase 1 dose-escalation study of combination
ruxolitinib and decitabine in patients with MPN-AP/BP conducted
through the Myeloproliferative Neoplasms Research Consortium
(MPN-RC 109 trial). Ruxolitinib at a dose of 25 mg twice daily (BID)
in the first cycle, followed by 10 mg BID in subsequent cycles, with
a fixed dose of decitabine 20 mg/m2 for the first 5 consecutive days
of a 28-day cycle was determined to be the recommended phase 2
dose.5 Overall response rate (complete remission [CR] 1 in-
complete platelet recovery [CRi]1 partial remission [PR]) was 9/17
(53%) and the median OS was 7.9 months (95% confidence
interval [CI], 4.1 months-not reached). Treatment emergent toxicity
and progression of disease were the most common reasons for
therapy discontinuation. Based on these encouraging results, we
conducted a phase 2 trial of this combination therapy regimen for
MPN-AP/BP patients with a primary objective of determining its
efficacy (NCT02076191).
Methods
This investigator-initiated MPN-RC clinical trial was conducted in
strict accordance with the principles of the Declaration of Helsinki
and Good Clinical Practice guidelines. Institutional ethical review
board approval of the protocol was required at each participating
institution and written informed consent was obtained from all
patients before screening. J.O.M. held the investigational new drug
application.
Eligible patients aged 18 years or older were required to have either
MPN-AP as defined by 10% to 19% blasts in either the peripheral
blood or BM, or MPN-BP as defined by $20% blasts in either
compartment with a documented prior diagnosis of essential
thrombocythemia (ET), polycythemia vera, or myelofibrosis (MF).
Patients with Eastern Cooperative Oncology Group performance
status scores of 0 to 3 were eligible.
Ruxolitinib was administered at a dose of 25 mg every 12 hours
orally in combination with decitabine at a dose of 20 mg/m2 IV daily
for 5 days, and repeated every 28 days. During the first cycle, single-
agent ruxolitinib was administered on days 1 through 28 (including
in combination with decitabine on days 8-12). After cycle 1,
ruxolitinib was administered at a dose of 10 mg BID on days 1
through 28 (including in combination with decitabine on days 8-12).
Criteria for dose modifications (treatment delays and interruptions)
of ruxolitinib and decitabine resulting from study drug-related
toxicity after cycle 1 is shown in supplemental Tables 1 and 2.
Patients were excluded from this study if they had received
chemotherapy or investigational therapy, with the exception of
hydroxyurea, within 4 weeks of study entry. Previous treatment with
either ruxolitinib or decitabine as single agents or prior hematopoi-
etic stem cell transplantation (HCT) was not a reason for exclusion.
Because of the metabolism by CYP3A4, strong inhibitors of
CYP3A4 were discontinued if possible and other inhibitors such as
grapefruit were discouraged. Best response by 6 months was the
prespecified primary end point for the study. The predetermined
secondary end point included characterizing the tolerability and
safety of ruxolitinib given at the recommended phase 2 dose in
combination with decitabine. Other secondary end points such as
survival were evaluated to compare clinical outcomes of this cohort
with prior studies conducted in this disease setting. Because
validated response criteria for MPN-AP/BP are not established,6
modified Cheson criteria were used for response assessment with
each cycle: CR was defined by 0% peripheral blood blasts,
leukocytes $4 3 109/L, hemoglobin $10 g/L, and platelets $100
3 109/L; CRi was defined by 0% peripheral blood blasts with
incomplete count recovery; PR was defined as $50% decrease in
peripheral blood blasts irrespective of blood counts.7 Overall
response rate (ORR) included CR, CRi, and PR. There are no
well-validated response criteria for MPN-AP/BP where there exists
both underlying MPN BM histomorphologic features and a concur-
rent AML clone. Given that a proportion of MPN-BP patients have
evidence of blasts $20% either exclusively in the peripheral blood
or the BM, BM pathologic review does not always allow for accurate
and reliable response assessment. It is important to recognize that
aspirates obtained in this setting are typically without spicules and
likely represent peripheral blood; therefore, we chose to rely on
peripheral blood blast clearance as a biomarker of response.
OS was defined as the time from first dose of ruxolitinib to death by
any cause. Patients were considered censored at the last known
date alive, if death was not documented. OS was estimated using
the Kaplan-Meier method and compared between groups by the
log-rank test. SAS version 9.4 (SAS Institute, Cary, NC) and R
version 3.6.2 were used for statistical analysis.
Genomic and cytogenetic analysis
DNA sequencing was performed using HemePACT-V4 targeted
panel, including 576 cancer genes associated with hematologic
malignancies, as previously described.8 Libraries were sequenced
on an Illumina HiSeq 2500 with 2 3 125 bp paired-end reads with
an average depth of ;5003. Sequencing reads were aligned to
human genome (hg19) using WA-MEM algorithm (v. 1-14-0)8 and
the data quality was assessed using FastQC (http://www.bioinfor-
matics.babraham.ac.uk/projects/fastqc). Mutations were called
using CAVEMAN (1.7.4),9 Mutect (4.0.1.2),10 Strelka (2.9.1),11
and PINDEL (1.5.4),10,12 and were subsequently annotated with the
Ensembl Variant Effect Predictor (VEP, version 86)13 and OncoKb.
14 A subset of all candidate mutations that were called by 2 callers
or matched a known somatic mutation that was retained for manual
annotation. The variants presented in this study are those that were
identified as pathogenic or likely pathogenic. BM metaphase cells
were obtained using standard technology and interphase fluores-
cence in situ hybridization scoring and analysis was previously
reported.
Luminex cytokine and chemokine analyses
The magnetic bead-based immunoassays for cytokines/chemo-
kines using the MILLIPLEX MAP Human Cytokine Panel 1 41-plex
panel (HCYTMAG-60k-PX41) (MilliporeSigma, St. Louis, MO) were
performed according to the manufacturer’s instructions. The
samples (25 mL) were analyzed in duplicate wells using a Luminex
FlexMap 3D (Luminex Corp., Austin, TX). The cytokine concen-
trations were determined by Luminex xPONENT v4.2 software. Six
control plasma samples (3 male, 3 female) collected from healthy
donors between the ages of 30 and 50 years were procured from
Allcells. Samples from 8 chronic-phase MF patients were used as
controls as well. Forty-two baseline plasma samples from the MPN-
RC 109 phase 1 and phase 2 trials were analyzed along with
corresponding cycle 1 day 8 (C1D8) samples, and cycle 2 day 1
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(C2D1; samples from 34 of the 42 patients were available).
Baseline cytokine levels from MPN-RC 109 phase 1/2 samples
were compared with normal controls and also with chronic-phase
MF samples. To determine if therapy with ruxolitinib or combination
ruxolitinib and decitabine resulted in alterations in the cytokine
profile of C1D8 and C2D1 samples compared with baseline in
those with samples available. Cytokine values below the limit of
detection were set at the lowest limit of detection and 13 cytokines
were excluded from statistical analysis because of having more than
50% of data below the limit of detection. Cytokines were averaged
in duplicate and transformed to log base 2 for all analysis with
corresponding log2 fold changes calculated. Heat maps were
generated for the analyzed cytokines and normalized. Statistical
analysis of cytokines included Wilcoxon rank-sum for independent
samples andWilcoxon signed-rank test for paired samples. P values
were not adjusted for multiple comparisons.
Results
Patient characteristics
Twenty-five patients were accrued to this study (Table 1) from
September 2016 through March 2017. The median age was
71 years (range, 47-86). At the time of study enrollment, 10 (40%)
had a diagnosis of MPN-AP and 15 (60%) MPN-BP. Six (24%) and
2 (8%) patients had prior exposure to ruxolitinib or decitabine,
respectively. None of the patients had received prior allogeneic
HCT. At MPN presentation, 5 (20%) patients were diagnosed with
MPN-AP/BP, 15 (60%) with MF (primary or secondary), and 5
(20%) with ET. At baseline, the median duration of time from MPN
diagnosis to study treatment was 72.9 months (range, 0.1-190) and
median palpable spleen length below the left costal margin was
7 cm (range, 0-20). An Eastern Cooperative Oncology Group
performance status score of 0-1 (17; 68%) was recorded in the
majority of patients.
Myeloid malignancy associated gene sequencing were performed
at baseline for 24/25 patients. A pathogenic or likely pathogenic
mutation was detected in 23/24 patients of this cohort, with
a median of 4.5 mutations per patient (range, 0-10), totaling 142
variants (Figure 1A-B). Of the total 142 mutations, JAK2V617F was
the most frequent mutation in this cohort (58%, 14/24). Other
common mutations included TP53 (38%, 9/24), TET2 (29%, 7/24),
SRSF2 (29%, 7/24), EZH2 (25%, 6/24), and ASXL1 (21%, 5/24)
(Figure 1A-B).
Cytogenetic results were available at baseline in 23 of the 25
enrolled patients (92%). An abnormal karyotype was detected in
20/23 (87%) patients. Complex abnormal karyotype, including
monosomal and hyperdiploid karyotype, was observed in 7/20
(35%) patients with an abnormal karyotype. The most frequent
chromosomal abnormality detected in 8/23 patients (35%) was
del(5q) (including band q31) in 6 patients, monosomy 5 (n5 1), and
i(5)(p10) resulting in the loss of the long arm (n5 1). Four of the 23
(17%) patients had a gain of the long arm of chromosome 1 in the
form of an unbalanced translocation with chromosomes 7, 12, 17,
and 18 resulting in trisomy 1q. Monosomy 17 was observed in 4/23
(17%) patients, and 3/23 (13%) patients had del(7q)/27. Balanced
translocations as the sole cytogenetic abnormality were seen in
2 patients: 1 with t(12;17)(p13;q23) karyotype and the other with
t(2;11)(p21;q23),t(12;19)(q15p13) karyotype.
Response
CRwas not observed in any patients (Table 2). CRi was observed in
2 (8.1%; 95% CI, 0.1-26.0) patients; PR was observed in 9 (36%;
95% CI, 18.0-57.5) patients; and no response was observed in 14
(56%; 95% CI, 34.9-75.6) patients. Response was not evaluable in
7 patients: 4 because of completion of ,1 cycle and withdrawal
from study secondary to an adverse event, 1 patient declined further
treatment, and 2 patients lacked baseline circulating blasts
(although circulating blasts were present at time of screening);
these patients were all deemed as nonresponders. The ORR (CR1
CRi 1 PR) was 11/25 (44%; 95% CI, 24.4-65.1). The median
number of cycles of therapy administered for both MPN-AP/BP
cohorts was 4.0 (range, 1-20 cycles; Figure 2). Median number of
cycles to best response was 4 cycles (range, 2-11 cycles) in 11
responders with amedian duration of response of 3.4 months (95%CI
2.1 to not estimated [NE]). Of the total cohort, 8/25 patients received
6 or more cycles of therapy. In the 2 patients who had 0% peripheral
blood blasts at baseline, 1 received 14 cycles of therapy and the other
had increased blast count at cycle 4 and proceeded to HCT.
Median peripheral blood blasts at baseline was 17.9% (range,
0-91), (12.0%; 0-18.8) in MPN-AP and 34% (0-91) in MPN-BP
(Table 1). Median peripheral blast count reduction of 54.8%
(2100% to 71.4%), was observed in patients with baseline blasts
(Figure 3). Among patients attaining a PR, 8/9 demonstrated
a blast count #5% in the peripheral blood at the time of response







Age (range), y 70.1 (46.7-85.6) 71.6 (52.4-81.4) 71.0 (46.7-85.6)
Female/male, n (%) 7 (70)/3 (30) 7 (46.7)/8 (53.3) 14 (56)/11 (44)
ECOG 0-1, n (%) 5 (50) 12 (80) 17 (68)
ECOG 2-3, n (%) 5 (50) 3 (20) 8 (32)
Disease duration before
therapy (range), mo
41.8 (0.1-190.5) 74.8 (0.7-177.3) 72.9 (0.1-190.5)
Spleen by palpation
(range), cm
8.0 (0-20) 6.0 (0-20.0) 7.0 (0-20.0)
Prior ruxolitinib, n (%) 3 (30.0) 3 (20) 6 (24)
Prior decitabine, n (%) 2 (20.0) 0 (0) 2 (8)
Peripheral blood blasts
(range), %
12.0 (0-18.8) 34 (0-91) 17.9 (0-91)
Bone marrow blasts
(range), %
7.3 (0-15) 28.0 (5.0-91.0) 15.0 (0.0-91.0)
Maximum of PB/BM blasts
(range), %
12.5 (10.0-18.8) 45.0 (20.9-91.0) 25.0 (10.0-91.0)
WBC count (range),
3109/L
6.0 (3.0-131.1) 8.7 (1.0-68.2) 6.6 (1.0-131.1)
Hematocrit (range), % 25.9 (21.6-34.4) 26.2 (22.4-37.4) 26.1 (21.6-37.4)
Platelet count (range),
3109/L
160.5 (44-1519) 39.0 (5-1166) 76.0 (5-1519)
Driver mutation present*,
n (%)
8 (80.0) 10 (71.4) 18 (75)
Abnormal karyotype†,
n (%)
8 (88.9) 12 (85.7) 20 (87)
ECOG, Eastern Cooperative Oncology Group; WBC, white blood cell.
*Baseline mutational status available on 24/25 patients.
†Baseline karyotype available on 23/25 patients.
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assessment. The median reduction in spleen size was 270.5%
(range, 2100% to 0%; Figure 4) in patients with a palpable spleen
at baseline. None of the patients with PHF6 mutation responded to
the treatment (3/3). No other mutations were associated with
response (CRi or PR) (supplemental Figure 2). Seven patients had
follow-up BM cytogenetics analysis. Complete cytogenetic responses
were seen in 3 patients at cycles 4, 10, and 16, respectively. Notably,
2 patients who achieved complete cytogenetic response had an OS
that exceeded the median survival of the entire cohort (10.2 months
and 20 months, respectively). In these 2 patients, the baseline
abnormalities were gains of genetic material of unknown origin
attached to chromosomes 1p and 3q and deletion of 5q, observed
in 1 patient, and trisomy of chromosomes 2 and 9 in the second
patient.
Central histopathology evaluation was performed on 20/25 patients;
5 patients were missing baseline specimens (2 not done, 3 unknown)



















































































































































































































Figure 1. Genomic data from patient speci-
mens at time of clinical trial enrollment. (A)
Genomic profile of somatic mutations in baseline
samples, as detected by next-generation sequencing
data. Each column represents a patient (n 5 24)
and each row in the top panel represents a gene
that carries at least 1 pathogenic or likely pathogenic
mutation (n 5 38). The upper bar plot indicates the
number of somatic mutation(s) per patient, colored
according to the type of the alteration, as described
in the legend. The right bar plot shows the number
of somatic mutations per gene. The frequency of
mutations in the cohort is listed on the left border of
the figure. The clinical response to treatment is dis-
played in the annotation bar at the lower axis of the
figure according to the legend. (B) Distribution of
mutations across all genes in the cohort. The bars
are colored according to the proportion of patient’s
response to the treatment. Color code: complete re-
mission with incomplete hematologic recovery (blue);
partial response (orange); no response (NR; red); re-
sponse not evaluable (N/E; gray).
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completion of ,4 cycles of therapy. BM fibrosis was assessed
using reticulin staining and BM blast percentage was assessed
based on morphology or immunohistochemical staining for CD34.
Both patients with CRi lacked BM fibrosis (MF-0) at baseline and
had markedly increased cellularity (BM cellularity of 80% and
100%) and an increase in BM blasts (25% and 10%). Follow-up
BM samples in both cases showed a marked reduction in cellularity
(30% cellularity in both cases) and blast counts ,5% with the
notable formation of clusters of erythroid cells in marked contrast to
baseline. Interestingly, end-of-treatment BM of both cases showed
increased BM fibrosis ($21 MF) and megakaryocytic histotopog-
raphy characteristic of chronic phase MF. In contrast to CRi
patients, evaluable BM slides from patients with no response
(NR; n 5 3) and PR (n 5 6) showed moderate or marked fibrosis
($21 MF) at baseline.
Safety
Adverse event (AE) assessment for all 25 enrolled patients was
recorded from time of treatment initiation to end of study visit.
Table 3 displays the AEs occurring in .10% of all patients,
regardless of attribution. The most frequent treatment emergent AE
(TEAE) experienced by patients (all grades) included fatigue
(8 patients, 32%), febrile neutropenia (7 patients, 28%), pneumonia
(7 patients, 28%), diarrhea (7 patients, 28%), abdominal pain
(6 patients, 24%), and edema (6 patients, 24%). Grade 3/4
hematologic AEs occurring in $5% of patients included neutrope-
nia (4 patients, 16%), anemia 4 (4 patients, 16%), and thrombo-
cytopenia (2 patients, 8%). Grade 3 and 4 nonhematologic TEAE
regardless of attribution occurring in $5% of patients included
Table 2. Best response by 6 months





CR Blasts 0%,WBC.43 109/L, hemoglobin
$ 10 g/L, platelets 100 3 109/L
0 (0) —
CR-i Blasts 0% incomplete count recovery 2 (8.1) 0.1-26.0
PR $50% decrease in peripheral blood
blasts, regardless of blood counts
9 (36.0) 18.0-57.5
NR Not meeting any of the above criteria 7 (28.0) 12.1-49.4
NR (secondary to
unevaluable)
Adverse event (n 5 4)*; refused further
treatment (n5 1); lack of baseline blasts
(n 5 2)
7 (28.0) 12.1-49.4
*Grade 5 pneumonia (n 5 1), grade 3 neutropenic fever, muscle weakness and fatigue
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14 16 18 20 22
Disease type AML/BP AP
* Death + Censored
End of response defined as peripheral blast count exceeding baseline value
Figure 2. Duration of treatment by disease group.
Corresponding clinical responses are indicated by symbols.
End of response is defined as peripheral blood blast count
exceeding baseline value. Overall survival time is also noted
in the figure.
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febrile neutropenia (7 patients, 28%), pneumonia (6 patients, 24%),
and bone pain (2 patients, 8%). Grade 3 and higher TEAEs were
comparable in patients with MPN-AP and MPN-BP.
All enrolled patients have ended treatment. Reasons for study
discontinuation included AE, 9 (36%); disease progression as
assessed by the treating physician, 7 (28%); physician decision,
2 (8%); HCT, 2 (8%); study closure, 2 (8%); patient withdrawal,
1 (4%); and unknown, 2 (8%). A total of 19 enrolled patients died on
study. Causes of death included disease progression (12 patients),
respiratory failure (4 patients), pneumonia (1 patient), sepsis (1 patient),
and unknown cause of death (1 patient). One death from sepsis with
underlying cause as disease progression occurred within 30 days of
treatment initiation.
Two patients were able to proceed to HCT. The first patient had
baseline peripheral blood blasts of 2%, and was deemed an NR by
response criteria resulting from rising blast count. The patient was
alive 6 months after HCT. The second patient had 0% peripheral
blood blasts at baseline (BM blasts were 28% at screening/
baseline), blast count increased to 7% at cycle 4 and a decision
to proceed to transplant. The patient died ;6.5 months after
transplant. Off-treatment reasons for the 11 patients who were






































Baseline PB blasts (%) displayed for each patient
MPN-AP MPN-BP
Figure 3. Maximum percentage change in peripheral
blood blasts by disease group. Median blast count
































Baseline spleen measurement (cm) displayed for each patient
Disease type Accelerated Phase MPN (10-19% blasts) Blast Phase MPN (20%+ blasts)
Figure 4. Maximum change in spleen size by
disease group. The median reduction in spleen size
across both MPN-AP/BP cohorts was 270.5% (range,
2100% to 0%).
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investigator decision (n 5 5), adverse event (n 5 4), and unknown
because of study closure (n 5 2).
Survival
The median OS for all patients on study was 9.5 (95% CI, 4.3-12.0)
months (Figure 5A). The median OS in responding patients was
9.5 months (5.8 to NE) and 9.7 months in nonresponders (3.6 to
NE). Median OS for TP53-mutated patients was 7.6 months (95%
CI, 4.3 to NE) vs 9.6 months (95% CI, 3.6 to NE) in TP53 wild-type
patients (P 5 .78) (Figure 5B). The number of gene mutations
(more than 4 vs less than 4) associated with myeloid malignancy
did not affect OS. Likewise, an association between response
and/or survival based on the molecular profile, clinical character-
istics, spleen size, or baseline peripheral blood blast count was not
identified.
Cytokine profiling of MPN-AP/BP
Compared with normal controls, MPN-AP/BP patients demon-
strated significantly higher levels of interleukin-8 (IL-8), tumor
necrosis factor-a (TNF-a; P , .01 for both), and interferon gamma-
induced protein 10 (P, .05) and significantly lower levels of endothelial
growth factor, platelet-derived growth factor-AA (P , .01 for both),
and platelet-derived growth factor-AB/BB (P , .05; Figure 6A-B). We
next compared baseline MPN-AP/BP samples with chronic-phase MF
samples (n 5 12). We identified significantly higher levels of eotaxin
(P, .05) andGRO-a (P, .01) in MPN-AP/BP samples, among others
(supplemental Figure 1A-B), both of which have previously been
noted to be elevated in essential thrombocythemia patients who
experience disease progression.15 Thus, at baseline, MPN-AP/BP
patients demonstrate increased levels of cytokines previously
associated with MPN disease progression. Among paired MPN-
AP/BP samples, after 8 days of ruxolitinib monotherapy, significant
decreases in TNF-a (consistent with prior observations in ruxolitinib-
treated MF patients16), interferon gamma-induced protein 10,
and IL-10 were noted, and a significant increase in eotaxin was
noted (P, .01 for all), compared with baseline samples. Evaluation
of baseline/pretreatment samples from C2D1 (after 1 cycle of
combination ruxolitinib and decitabine) demonstrated significant
changes in several cytokines not observed after 8 days of ruxolitinib
monotherapy, including increases in granulocyte-macrophage
colony-stimulating factor, interferon-a2, interferon-g (P , .05 for
all), IL-6 levels (P , .01), and decreases in IL-1Ra (P , .01) when
compared with baseline study samples. Notably, there was a trend
toward significantly higher levels of IL-8 (P 5 .05) and vascular
endothelial growth factor (P5 .05) at baseline in patients who were
responders to therapy vs nonresponders.
Discussion
The outcomes of patients with advanced phase MPN are poor, and
unearthing the mechanisms of progression represents an area of
active translational research.17 We have previously determined that
ruxolitinib administered at a dose of 25 mg BID for the first cycle and
10 mg BID for subsequent cycles can be safely and effectively
combined with a fixed dose of decitabine in patients with MPN-AP/
BP. In this multicenter phase 2, open label, combination study of
ruxolitinib and decitabine, the ORR rate was 44%with a median OS
of 9.5 months, which compares favorably with historical data of 3 to
5 months for conventional AML induction chemotherapy in this
population.2
A previous retrospective study by Masarova et al showed that even
the presence of at least 4% peripheral blood blasts identifies
a population of MF patients that has a similarly poor outcome and
clinical characteristics as MF-AP patients.18 Peripheral blood blast
percentage is a continuum and can fluctuate during the clinical
course and frequently differ between the peripheral blood and
BM compartments at any given point in time. It is important to note
that the clinical and cytogenomic profiles of the AP and BP cohorts
were in fact overlapping in clinical characteristics and consequently
outcome.
Two single-institution phase 2 trials of single-agent ruxolitinib in
patients with AML have reported modest responses selectively in
those patients harboring mutated JAK2.19,20 Decitabine mono-
therapy has been reported to extend survival to 9 to 10 months in
the setting of advanced phase MPN, and is a better tolerated
alternative to more intensive induction chemotherapy regimens.21,22
The activity of combination ruxolitinib and azacytidine in patients
with chronic phase MF was demonstrated by the MD Anderson
group previously, and a high rate of spleen response coupled
with reductions in BM fibrosis was noted in this phase 2 trial.18
Additionally. Bose et al recently reported the results of their single-
institution, phase 1/2 trial of combination ruxolitinib and decitabine in
an exclusively MPN-BP population with a recommended phase 2
dose of ruxolitinib 50 mg BID.23 The ORR was 61% with a median
OS of 8.4 months in this study. Given the results presented here, it
is unclear that there is a survival advantage associated with
ruxolitinib doses higher than 10 mg twice daily when administered
in combination with a hypomethylating agent for advanced phase
MPN patients.
Table 3. Adverse events occurring in >10% of patients, regardless of
attribution
Adverse event Grade 1/2 Grade 31 Any grade
Hematologic, n (%)
Neutropenia 1 (4) 4 (16) 5 (20)
Anemia 1 (4) 4 (16) 5 (20)
Thrombocytopenia 3 (12) 2 (8) 5 (20)
Nonhematologic, n (%)
Fatigue 7 (28) 1 (4) 8 (32)
Febrile neutropenia 7 (28) 7 (28)
Pneumonia 1 (4) 6 (24) 7 (28)
Diarrhea 6 (24) 1 (4) 7 (28)
Abdominal pain 6 (24) 6 (24)
Edema 6 (24) 6 (24)
Constipation 5 (20) 5 (20)
Epistaxis 3 (12) 1 (4) 4 (16)
Vomiting 4 (16) 4 (16)
Abdominal distension 3 (12) 3 (12)
Dyspnea 3 (12) 3 (12)
Dizziness 3 (12) 3 (12)
Headache 2 (8) 1 (4) 3 (12)
Hypertension 2 (8) 1 (4) 3 (12)
Bone pain 1 (4) 2 (8) 3 (12)
Myalgia 3 (12) 3 (12)
Pain 3 (12) 3 (12)
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The survival outcome reported in our study is comparable to data
from a single-institution retrospective report of a median OS of
9.4 months with curative-intent intensive induction therapy
followed by HCT.22 The study also reported a median OS of only
2.3 months for those treated with noncurative-intent low intensity
therapy, which included hypomethylating agents. Based on the
data from the prospective trial presented here, it remains
somewhat unclear if the addition of ruxolitinib improves response
rate, as well as duration of response, over single-agent decitabine.
However, these results do support the ability of this regimen to
reduce spleen burden (median reduction, 254.8%) in these
advanced phase patients, which would be expected to have
a positive impact on quality of life.24
TP53 mutations are among the most common and vexing
mutations encountered in advanced MPN.25,26 Clinical observa-
tions in patients with AML harboring TP53 mutations, often with
concurrent complex karyotypes, have demonstrated that these
patients have inferior remission rates and survival when treated
with induction chemotherapy.25,27 By contrast, recent data have
demonstrated that presence of TP53 mutations is associated with
higher response rates to decitabine (10-day regimen) in AML than
that observed in TP53 wild-type cases. Further, TP53 mutations
were not associated with inferior survival in AML patients treated
with decitabine. Finally, a substantial decrease in TP53 variant allele
frequency was observed in a subset of treated patients.28 Similar to
these observations, the presence of TP53 mutations (which were
observed in 38% of patients treated in our study) was not associated
with a reduced response rate, nor with a reduced OS rate to ruxolitinib
and decitabine therapy as compared with TP53 wild-type patients.
Given the relatively small number of patients in this study, these data
must be interpretedwith caution. However, our data suggest that TP53
mutations may not influence outcomes in patients with MPN-AP/BP
treated with decitabine. This observation will require further validation
in larger retrospective and prospective studies.
Inflammatory cytokine production is a key component of MPN
pathophysiology and has been well described in chronic phase
MPN.15,16,29,30 To our knowledge, the cytokine profile of MPN-AP/
BP has not been described previously. We identified significantly
higher levels of IL-8 and TNF-a in MPN-AP/BP compared with normal
controls. Notably, IL-8 expression has previously been associated
with inferior overall and leukemia-free survival in MF patients,31 and
TNF-a is known to be overexpressed in MPN patients and correlates
with JAK2V617F allele burden (itself a marker of more advanced
disease).32 These data support the possibility that such inflammatory
cytokines contribute to MPN disease progression, the pathobiology
of which remains to be investigated.
Recognized, and previously acknowledged, limitations of this study
include the heterogeneity of the population which included both
MPN-AP and MPN-BP patients, absence of standard response
criteria, as well as technical challenges involved in BM assessments
in this patient population. This study population was a real-world
mixture of advanced phase patients that ranged from MPN-AP to
MPN-BP with frequent discordance between peripheral blood and
BM blast percentage. The heterogeneity of the patient population
was further emphasized by the recruitment and treatment of
subjects enrolled across 7 US centers. The clinical significance of
peripheral blood blast cell count clearance on survival outcome is
not evident from this dataset because there was no clear correlation
between ORR and survival. It is also notable the MPN-AP patients
had a baseline median blast count (17.9%) that approached
MPN-BP threshold (20%) and otherwise indistinguishable molec-
ular profiles, including p53 and complex karyotype, from the MPN-BP
cohort, so these may actually be closely overlapping populations.
Future studies evaluating novel treatment approaches in advanced
phase MPN patients should be powered sufficiently for separate
analysis of primary end points in each group and use validated
response criteria. The lack of patient-reported outcome data in the



























































Figure 5. Survival analysis of MPN-AP/BP
patients treated with combination decitabine
and ruxolitinib. (A) OS from the time of study
enrollment. The median OS for all patients on study
was 9.5 (95% CI, 4.3-12.0) months. (B) OS by TP53
status. Median OS for TP53 mutated patients was
7.6 (95% CI, 4.3-NE) and 9.6 (95% CI, 3.6-NE)
months in TP53 nonmutated patients (P 5 .78).

















L user on 08 D
ecem
ber 2020
symptom response in this trial, which is an important consider-
ation when developing therapies that may potentially extend
survival while aiming to maintain quality of life. However, we do
note dynamic changes in inflammatory cytokines in response to
therapy, which may correlate with symptom burden changes, as
previously described.16
MPN-AP/BP is a genetically complex, treatment-resistant, and
debilitating disease in dire need of improved interventions. Referral
to centers for clinical trial participation will remain of significant
importance as novel treatment approaches are evaluated in the
future, whereas the goal for a subset of eligible patients may
still be HCT consolidation. The combination of ruxolitinib and
decitabine in MPN-AP/BP is a viable low-intensity, ambulatory
regimen that reduces spleen size with a median OS that is
particularly encouraging given multiple historical reports. Outside of
clinical trial options, this therapeutic approach should be considered
in those patients with leukemic evolution of chronic MPN and may
serve as a potential treatment bridge to HCT in a subset of patient,
which remains the only curative option.
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Figure 6. Baseline and dynamic changes in cytokine levels in patients with MPN-AP/BP treated with combination decitabine and ruxolitinib. (A) Heatmap of
evaluated cytokines for MPN-AP/BP baseline samples, C1D8, C2D1, and control samples. Cytokines are normalized across the comparison groups. Each row constitutes 1
cytokine, with the data for individual patients organized in columns. Green and red denote markers that are present at lower and higher levels, respectively. (B) Log2 fold
changes shown for evaluated cytokines. Comparisons consisted of baseline vs control, C1D8 vs baseline, and C2D1 vs baseline.
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